Teladoc Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
$2.56B revenue 2024; Q2 2025 $631.9M (-1.6% YoY); 101-103M projected US members 2025; telehealth market leader; telehealth market $123.26B 2024 to $455.27B 2030; 46.58% North America share
About
Teladoc Health is the world's largest telehealth company, founded in 2002 and headquartered in Purchase, New York, that pioneered on-demand virtual healthcare delivery in the United States. The company was founded on the premise that patients should be able to access physicians anytime and anywhere without traveling to a physical office — a model that took over a decade to gain mainstream acceptance before becoming a necessity during the COVID-19 pandemic. Teladoc's mission is to provide whole-person virtual care that addresses physical health, mental health, and chronic condition management through an integrated digital platform.\n\nTeladoc's platform encompasses general medical, dermatology, nutrition, and specialty care through its core telehealth offering; mental health and therapy through BetterHelp, the world's largest online therapy platform; virtual primary care and chronic condition management through Teladoc Primary360; and complex care navigation through its integrated whole-person health approach. The company serves employers, health plans, hospitals, and health systems, delivering virtual care to members across the US and internationally. BetterHelp has become a significant consumer-facing revenue driver, connecting individuals directly with licensed therapists without employer or insurance intermediaries.\n\nTeladoc reported $2.56 billion in revenue for 2024 and projects 101 to 103 million US members in 2025. The company trades on the NYSE under TDOC and holds a substantial lead in telehealth market share through its scale, multi-specialty breadth, and direct-to-consumer mental health reach via BetterHelp. Despite post-pandemic normalization and the $13.7 billion Livongo write-down in 2022, Teladoc remains the largest and most diversified virtual care platform, with continued investment in AI-powered clinical decision support and chronic disease management to drive the next phase of growth.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.